Barclays PLC Buys 55,497 Shares of Inozyme Pharma, Inc. (NASDAQ:INZY)

Barclays PLC boosted its position in shares of Inozyme Pharma, Inc. (NASDAQ:INZY) by 261.4% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 76,730 shares of the company’s stock after acquiring an additional 55,497 shares during the period. Barclays PLC owned 0.12% of Inozyme Pharma worth $401,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Eventide Asset Management LLC raised its position in shares of Inozyme Pharma by 5.0% during the 3rd quarter. Eventide Asset Management LLC now owns 4,134,436 shares of the company’s stock valued at $21,623,000 after purchasing an additional 198,216 shares during the period. Samlyn Capital LLC raised its holdings in Inozyme Pharma by 15.0% during the second quarter. Samlyn Capital LLC now owns 3,350,535 shares of the company’s stock valued at $14,943,000 after acquiring an additional 437,622 shares during the period. Affinity Asset Advisors LLC lifted its position in shares of Inozyme Pharma by 8.1% in the second quarter. Affinity Asset Advisors LLC now owns 2,856,252 shares of the company’s stock valued at $12,739,000 after acquiring an additional 213,733 shares in the last quarter. Millennium Management LLC boosted its stake in shares of Inozyme Pharma by 154.1% in the second quarter. Millennium Management LLC now owns 1,787,947 shares of the company’s stock worth $7,974,000 after acquiring an additional 1,084,341 shares during the period. Finally, State Street Corp grew its position in shares of Inozyme Pharma by 5.0% during the third quarter. State Street Corp now owns 1,050,420 shares of the company’s stock worth $5,494,000 after purchasing an additional 50,386 shares in the last quarter. Hedge funds and other institutional investors own 88.30% of the company’s stock.

Inozyme Pharma Stock Performance

Inozyme Pharma stock opened at $3.07 on Friday. The company has a quick ratio of 7.68, a current ratio of 7.68 and a debt-to-equity ratio of 0.51. Inozyme Pharma, Inc. has a twelve month low of $2.38 and a twelve month high of $7.80. The company’s 50-day moving average price is $3.20 and its 200-day moving average price is $4.44. The company has a market cap of $197.22 million, a PE ratio of -1.97 and a beta of 1.37.

Inozyme Pharma (NASDAQ:INZY) last issued its quarterly earnings data on Tuesday, November 5th. The company reported ($0.39) earnings per share for the quarter, topping the consensus estimate of ($0.44) by $0.05. On average, equities research analysts forecast that Inozyme Pharma, Inc. will post -1.59 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

INZY has been the topic of a number of research analyst reports. Raymond James initiated coverage on Inozyme Pharma in a research note on Thursday, December 12th. They issued an “outperform” rating and a $26.00 price target for the company. HC Wainwright restated a “buy” rating and set a $14.00 target price on shares of Inozyme Pharma in a research report on Wednesday, November 6th. Needham & Company LLC reiterated a “buy” rating and issued a $23.00 price target on shares of Inozyme Pharma in a report on Wednesday, November 6th. Stifel Nicolaus began coverage on shares of Inozyme Pharma in a report on Thursday, September 12th. They set a “buy” rating and a $16.00 price objective for the company. Finally, Wedbush reaffirmed an “outperform” rating and issued a $12.00 target price (down from $15.00) on shares of Inozyme Pharma in a report on Tuesday, November 5th. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $17.00.

About Inozyme Pharma

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.